Repligen Co. (NASDAQ:RGEN) VP Sells $739,716.55 in Stock

Repligen Co. (NASDAQ:RGEN) VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Repligen Trading Down 2.4 %

Shares of Repligen stock opened at $161.67 on Friday. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.65. The company has a market capitalization of $9.06 billion, a P/E ratio of 646.71, a PEG ratio of 5.98 and a beta of 0.95. The company’s fifty day moving average is $134.92 and its two-hundred day moving average is $166.00.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same period last year, the firm posted $0.53 EPS. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis. Analysts forecast that Repligen Co. will post 1.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC grew its position in Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 60 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Repligen by 0.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after acquiring an additional 62 shares during the period. abrdn plc lifted its stake in shares of Repligen by 1.4% in the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after acquiring an additional 71 shares during the period. Commerce Bank lifted its stake in shares of Repligen by 4.5% in the 4th quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 72 shares during the period. Finally, Quadrant Capital Group LLC lifted its stake in shares of Repligen by 15.1% in the 4th quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 85 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on RGEN. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and dropped their price objective for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Royal Bank of Canada reissued an “outperform” rating and issued a $190.00 price objective on shares of Repligen in a research report on Wednesday. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Guggenheim started coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $189.57.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.